CTS™ Dynabeads™ CD3/CD28 are intended for ex vivo isolation, activation, and expansion of human T-cells in translational research. The technology—previously known as Xcyte™ Dynabeads™ or Dynabeads™ ClinExVivo™ CD3/CD28—has been used in a number of clinical studies. By combining anti-CD3 and anti-CD28 antibodies on Dynabeads, the beads provide both the primary and co-stimulatory signals that are required for activation and expansion of T cells. CTS Dynabeads CD3/CD28 are manufactured and controlled according to ISO 9001:2000 and ISO 13485:2012 requirements. A Device Master File is held with the FDA for cross-referencing in IND applications, and a CoA is available on request. In the US, CTS Dynabeads CD3/CD28 are available for clinical use only under an approved Investigational New Drug (IND) application. Dynabeads™ Human T-Expander CD3/CD28 (Cat. No. 11141D) is the research grade version of CTS Dynabeads CD3/CD28, containing the same amount and ratio of antibodies from the same clones as CTS Dynabeads CD3/CD28, and intended for small scale pre-clinical research.
The CTS Dynabeads CD3/CD28 technology has been successfully used in ex vivo isolation, activation, and expansion of T-cells in a number of studies, including studies on HIV infection and cancer. Other potential applications for this novel technology include research into treatment of autoimmune and infectious diseases and prevention of complications associated with chemotherapy and allogeneic stem cell transplantation.